GALECTIN THERAPEUTICS INC

Item 5.

Other Information

2025 Annual Meeting of Stockholders

The Board of Directors has set the date for the Company’s 2025 Annual Meeting as December 3, 2025. The meeting will be a virtual meeting conducted by live webcast on the internet. Additional details regarding the 2025 Annual Meeting, including the time and matters to be voted upon, will be set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting to be filed with the SEC.

As the date of the 2025 Annual Meeting has changed by more than 30 days from the one-year anniversary of the 2024 Annual Meeting, the Company is informing stockholders of this change in accordance with Rule 14a-5(f) under the Exchange Act, and it is also informing stockholders of the new dates described below for submitting stockholder proposals and other matters.

Pursuant to Rule 14a-8 of the Exchange Act, any stockholder intending to present a proposal for inclusion in the proxy statement for the 2025 Annual Meeting must provide timely written notice of the proposal to the Corporate Secretary at 4960 Peachtree Industrial Blvd., Suite 240, Norcross, GA 30071. The Company must receive the proposal by September 1, 2025 for possible inclusion in the proxy statement, which the Company has determined to be a reasonable time before the Company expects to begin to print and send its proxy materials in accordance with Rule 14a-8(e).

Additionally, under the Company’s bylaws, any stockholder of record intending to nominate a candidate for election to the Board or to propose any business at the 2025 Annual Meeting must give timely written notice to the Corporate Secretary at 4960 Peachtree Industrial Blvd., Suite 240, Norcross, GA 30071. A nomination or proposal for the 2025 Annual Meeting will be considered timely if it is received no later than the close of business on August 25, 2025 (the 10th day following the day on which public announcement of the date of the 2025 Annual Meeting is first made).

Securities Trading Plans of Directors and Executive Officers

All three executive officers of the Company, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement”,, as defined in Regulation S-K Item 408, during the fiscal quarter ended June 30, 2025.